ICICI Securities recommends a sell on Divi's Laboratories with a target price of Rs 4,500 despite recent quarterly growth. Management remains optimistic about future revenue growth driven by custom synthesis and new projects. Promoters hold a significant 51.89% stake, with FIIs and DIIs owning substantial shares. The company aims for commercial success in its Kakinada plant.
